David Liu (courtesy Broad Institute)
David Liu's biotech shoots for $150M+ IPO raise to develop CRISPR 3.0
Last quarter’s biotech IPO raise was the lowest in five years, but the team at Prime Medicine thinks their “holy crap …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
